BOSTON, Nov. 26 /PRNewswire/ -- Surface Logix, Inc. today announced that Jim Mahoney, President and Chief Executive Officer, will present an update of the company's drug development pipeline at the 19th Annual Piper Jaffray Health Care Conference being held November 27-29, 2007 at The Pierre Hotel in New York City. Mr. Mahoney's presentation will take place on Wednesday, November 28, 2007 at 2:50 PM EST.
Surface Logix currently has two programs in human clinical trials with a third program in the IND preparation stage. Mr. Mahoney will discuss the latest results for SLx-2101 and SLx-4090. SLx-2101, a second-generation PDE5 inhibitor designed to address cardiovascular indications, is currently in two separate Phase 2a trials, one in hypertension and another in Raynaud's syndrome. SLx-4090, a first-in-class enterocyte-specific MTP inhibitor for the treatment of dyslipidemia and potentially other indications, is also in Phase 2a.
About Surface Logix, Inc.
Surface Logix, Inc. uses its expertise in biophysical chemistry to
create and develop novel small molecule drugs (NCEs) with superior
drug-like properties that are clearly differentiated from competitive
products. The company is advancing multiple internal programs focused
primarily on cardiovascular, metabolic, oncologic and fibrotic diseases.
For more information, please visit http://www.surfacelogix.com.
Leland Webster, Ph.D., M.B.A.
Surface Logix Inc.
Vice President, Corporate Development
MacDougall Biomedical Communications, Inc.
|SOURCE Surface Logix, Inc.|
Copyright©2007 PR Newswire.
All rights reserved